case report | Q2782326 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1046621399 |
P356 | DOI | 10.1186/S13569-016-0065-Z |
P932 | PMC publication ID | 5223331 |
P698 | PubMed publication ID | 28078078 |
P50 | author | Annalisa Astolfi | Q57015938 |
P2093 | author name string | G Biasco | |
A D Pinna | |||
M A Pantaleo | |||
G Beltramo | |||
G Brandi | |||
G Ercolani | |||
G P Frezza | |||
L Gatto | |||
M Nannini | |||
M Saponara | |||
M Urbini | |||
V Di Scioscio | |||
P2860 | cites work | Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors | Q28118852 |
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Q28268831 | ||
Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis | Q32049769 | ||
Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. | Q34155715 | ||
PDGFRA activating mutations in gastrointestinal stromal tumors. | Q34169772 | ||
The effect of surgery and grade on outcome of gastrointestinal stromal tumors | Q34214793 | ||
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). | Q34274467 | ||
External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors | Q34461532 | ||
Clinical management of gastrointestinal stromal tumors: before and after STI-571. | Q34524907 | ||
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q34645665 | ||
Successful treatment of gastrointestinal stromal tumor with multiple liver metastases with radiofrequency ablation and imatinib: A case report | Q35871522 | ||
Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma | Q36360832 | ||
Gastrointestinal stromal tumors: report of an audit and review of the literature | Q37428518 | ||
Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). | Q37474435 | ||
CyberKnife radiosurgery for brain metastases | Q37975026 | ||
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study | Q38406965 | ||
Safety and Efficacy of Radiofrequency Ablation for Hepatic Metastases from Gastrointestinal Stromal Tumor | Q38646758 | ||
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity | Q39896194 | ||
Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells | Q40334015 | ||
Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor | Q41282761 | ||
Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report. | Q45938674 | ||
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57570640 | ||
P304 | page(s) | 1 | |
P577 | publication date | 2017-01-10 | |
P1433 | published in | Clinical Sarcoma Research | Q27724025 |
P1476 | title | Radiotherapy in the management of gist: state of the art and new potential scenarios | |
P478 | volume | 7 |
Q58794940 | Current treatment strategies in pediatric gastrointestinal stromal cell tumor |
Q88093670 | Management of rectal gastrointestinal stromal tumor |
Q48536660 | Radiotherapy for Gastrointestinal Stromal Tumors |
Q47120963 | Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy |
Q47094732 | The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression. |